RESEARCH INVENTION JOURNAL OF RESEARCH IN MEDICAL SCIENCES 5(1):87-91, 2026

©RIJRMS Publications

ONLINE ISSN: 1115- 6198

Print ISSN: 1597-3107

https://doi.org/10.59298/RIJRMS/2026/518791

Monoclonal Antibody Prophylaxis Against Plasmodium Falciparum Infection in High-Transmission Settings

Mugisha Emmanuel K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Plasmodium falciparum malaria remained a formidable public health challenge in high-transmission regions, particularly sub-Saharan Africa. Despite existing control measures, malaria continues to cause significant morbidity and mortality, underlining the urgent need for novel prevention strategies. Monoclonal antibodies (mAbs) have emerged as promising prophylactic agents due to their targeted specificity and potential for durable protection. This review aimed to critically evaluate the current status and future prospects of monoclonal antibody prophylaxis against P. falciparum infection in high-transmission settings, focusing on efficacy, safety, delivery platforms, and implementation challenges. A comprehensive literature search was conducted encompassing peer-reviewed clinical trials, systematic reviews, WHO reports, and preclinical studies published primarily within the last decade, addressing monoclonal antibodies targeting P. falciparum in endemic populations. Several long-acting mAbs targeting the circumsporozoite protein (CSP) of P. falciparum demonstrated high-level, durable protection exceeding 75% efficacy over transmission seasons following single-dose administration in adults and children. CIS43LS and related Fc-engineered antibodies show extended half-lives with successful intravenous and subcutaneous delivery, with manageable safety profiles including low incidence of infusion-related adverse events. Emerging candidates and newer antibodies targeting multiple epitopes hold promise for broader and longer-lasting efficacy. Challenges included optimizing dosing routes and schedules suitable for large-scale use, ensuring efficacy in vulnerable groups such as infants and pregnant women, cost considerations, and integration with existing malaria control interventions. Monoclonal antibodies represented a transformative prophylactic modality against P. falciparum in high-transmission settings, offering a potentially scalable complement to vaccines and chemoprevention. Continued clinical evaluation, refinement of delivery systems, and policy frameworks are essential to maximize the public health impact of this innovative approach.

Keywords: Monoclonal antibodies, Plasmodium falciparum, Malaria prophylaxis, High transmission, Circumsporozoite protein.

INTRODUCTION

Plasmodium falciparum is the most lethal species of malaria parasite, responsible for the majority of global malaria morbidity and mortality, predominantly in tropical and subtropical regions with intense transmission dynamics [1]. The parasite's complex life cycle, involving both human and Anopheles mosquito hosts, and the ability to evade host immunity have complicated effective control and elimination efforts. Despite decades of vector control, antimalarial drugs, and recently licensed vaccines, malaria prevention remains a formidable challenge in high-burden areas, with over 271 million cases and nearly 627,000 deaths annually, mainly in children under five [2, 3].

Monoclonal antibodies (mAbs) have recently emerged as targeted prophylactic agents against infectious diseases, leveraging their high specificity to neutralize pathogens or their toxins. Unlike vaccines that stimulate host immune responses, mAbs confer passive immunity by directly binding to parasite antigens, offering immediate protection. In malaria, the circumsporozoite protein (CSP) on the sporozoite surface is a validated target for mAbs, capable of blocking parasite invasion of hepatocytes and subsequent blood-stage infection. Advances in antibody engineering have yielded long-acting mAbs with extended half-lives, facilitating season-long protection with a single dose, a desirable attribute for high-transmission settings [4].

The introduction of mAb prophylaxis opens new avenues for malaria prevention, particularly for populations inadequately protected by existing measures. However, its practical utility depends on comprehensive understanding of efficacy, safety, pharmacokinetics, optimal delivery methods, and integration within broader malaria control frameworks. This review critically appraises the current evidence on monoclonal antibody prophylaxis against P. falciparum infection, encompassing established and emerging candidates, in high-transmission regions [5].

Molecular Mechanism and Biochemical Basis of Monoclonal Antibody Prophylaxis

Monoclonal antibodies designed for malaria prophylaxis predominantly target the circumsporozoite protein (CSP), the major surface antigen expressed on P. falciparum sporozoites, responsible for hepatocyte invasion. CSP contains repetitive NANP motifs and a C-terminal thrombospondin-like domain, both of which are critical for sporozoite motility and infection. Binding of mAbs to these epitopes inhibits sporozoite traversal and entry into liver cells, thereby interrupting the early stages of infection [6].

For example, CIS43LS is a human IgG1 monoclonal antibody selectively engineered with Fc modifications to extend serum half-life, thereby maintaining protective concentrations over several months with a single administration. Its mechanism involves high-affinity binding to a junctional epitope bridging the NANP repeats and C-terminal region, neutralizing sporozoite infectivity. Other antibodies such as L9LS and MAM01 similarly target distinct CSP epitopes or multiple binding sites, which may enhance protective breadth and durability [7].

These antibodies employ passive immunization, differentiating them from active immunization strategies by introducing exogenous antibodies rather than eliciting host antibody production. This direct approach offers immediate protection, bypassing the variable host immune response, which is often compromised in young children or immunocompromised individuals.

Technological advances in antibody engineering, such as Fc glycoengineering and half-life extension mutations, optimize pharmacokinetics and effector functions, including improved binding to neonatal Fc receptors (FcRn) for prolonged circulation and potential engagement of immune effector mechanisms. However, the limited duration of protection relative to vaccines and the necessity for parenteral administration remain barriers to be addressed [8]. Monoclonal antibodies achieve prophylaxis through targeted neutralization of P. falciparum sporozoites at the liver invasion stage, facilitated by sophisticated bioengineering techniques enhancing durability and function.

Analytical and Clinical Evaluation Methods

Monoclonal antibody efficacy and safety assessments have utilized randomized, placebo-controlled clinical trials with both experimental human infection models and field-based studies in endemic populations. The pivotal Phase 1 trial of CIS43LS employed controlled human malaria infection (CHMI) in malaria-naïve adults, demonstrating over 80% protection against infection following a single intravenous dose. Subsequent extended Phase 2 and 3 trials evaluated protection durability during endemic transmission seasons in African children and adults [9].

Standard efficacy endpoints include reduction in time to first P. falciparum infection, clinical malaria episodes, parasitemia prevalence, and severe malaria incidence. Pharmacokinetic analyses quantify serum antibody concentrations, bioavailability, and half-life, typically ranging from 50 to over 90 days, correlated with protective thresholds. Safety profiles are assessed through monitoring of infusion-related reactions, hypersensitivity, immunogenicity (antidrug antibodies), and other adverse events over both short- and long-term follow-ups [10].

Subcutaneous administration emerges as a key modality for ease of delivery compared to intravenous infusion, with bioavailability studies confirming approximately 60% systemic absorption and comparable safety. Laboratory assays, including ELISA for antibody levels, sporozoite neutralization assays, and in vitro hepatocyte invasion inhibition tests, provide mechanistic insights linking antibody concentration to functional efficacy [11]. Strengths of these methods include rigorous controlled conditions and increasingly representative real-world settings. Limitations include small sample sizes in early studies, especially for vulnerable populations such as infants and pregnant women, and variable transmission intensities affecting efficacy estimates. Long-term safety data remain limited, necessitating ongoing pharmacovigilance. Current clinical and analytical methods provide robust, if evolving, frameworks to validate monoclonal antibody prophylaxis efficacy and safety in malaria-endemic populations.

Clinical and Public Health Implications in High-Transmission Settings

The introduction of monoclonal antibody prophylaxis in high-transmission regions promises a paradigm shift in malaria prevention, supplementing existing interventions such as insecticide-treated nets (ITNs), indoor residual spraying, seasonal malaria chemoprevention (SMC), and vaccines. Clinical trials indicate that long-acting mAbs confer high-level protection with efficacy estimates ranging between 75 and 88% against P. falciparum infection over a 5 to 6-month malaria season in endemic areas [12].

Such durable protection is particularly advantageous for infants, children, and pregnant women who bear the highest disease burden and for whom vaccine-induced immunity may be suboptimal. Monoclonal antibodies can be administered intermittently, aligned with transmission seasons, potentially reducing the logistical challenges associated with repeated drug dosing and vaccination campaigns. Importantly, the passive immunity imparted does

not require host immune competence, offering protection to immunologically naïve or compromised individuals [13].

Public health modeling suggests that incorporating monoclonal antibodies could reduce malaria incidence, transmission, and mortality substantially when coverage is optimized, with potential synergistic effects when combined with other control measures. Moreover, mAbs could fill gaps where resistance to antimalarial drugs or insecticides compromises effectiveness [14].

However, deployment faces key challenges including high manufacturing costs, cold chain requirements, and the need for parenteral administration in resource-limited settings. Scalability and equitable access remain concerns, particularly for rural and marginalized populations. Integration into routine immunization or malaria control programs requires comprehensive policy frameworks and health system strengthening. Monoclonal antibody prophylaxis holds promise to significantly reduce malaria burden in high-transmission areas, though operational and economic hurdles must be surmounted for maximal public health impact.

Therapeutic and Translational Developments

Monoclonal antibody development against P. falciparum leverages advanced recombinant DNA technology, Fc engineering, and high-throughput antibody discovery platforms to generate candidates with improved potency and pharmacokinetics. The translation from bench to bedside is exemplified by CIS43LS, which underwent rapid progression from discovery to human trials, highlighting the feasibility of developing mAbs for infectious diseases beyond conventional targets [15].

Emerging antibodies are being engineered to target multiple sporozoite epitopes or combine with other antimalarial interventions for enhanced efficacy. The half-life extension mutations in antibody Fc domains, such as LS (M428L/N434S), double FcRn binding, allowing reduced dosing frequency and volume, facilitating single-dose administration per transmission season [16]. Advances also focus on alternative delivery routes, including subcutaneous injections, which increase feasibility and acceptability in endemic regions, alongside studies on intramuscular or depot formulations for sustained release. Combination therapies with monoclonal antibodies and vaccines or chemoprophylactics are under evaluation to maximize protection and mitigate resistance risks [17].

Cost-effective manufacturing is a priority, with bioprocessing innovations enabling large-scale antibody production and potential use of plant or microbial expression systems to reduce expenses. The development of standardized monoclonal antibody reagents and reference materials advances regulatory and clinical evaluation [18]. These translational efforts underscore a vibrant pipeline poised to expand the utility of monoclonal antibodies in malaria prophylaxis and potentially broader tropical infectious disease control.

Gaps, Controversies, and Future Research Directions

Significant knowledge gaps persist regarding long-term safety, immunogenicity, and efficacy of monoclonal antibodies in diverse populations, including infants, pregnant women, and immunocompromised persons. While initial results in adults and older children are encouraging, extrapolation to younger and vulnerable groups requires rigorous clinical investigation [19]. Debate exists concerning the cost-effectiveness and sustainability of mAb prophylaxis compared to established tools, especially in resource-poor, high-burden settings. High production costs and cold chain logistics may limit wide-scale implementation unless substantial price reductions and delivery optimizations are achieved [20].

Uncertainties surround potential resistance development to monoclonal antibodies, though mechanisms remain speculative at present. Monitoring for target antigen polymorphisms and escape mutants is critical to sustain efficacy. Ethical considerations include equitable access and prioritization in populations most at risk [21].

Future research priorities include development of next-generation mAbs with improved potency and breadth, pan-Plasmodium reactivity, and alternative delivery platforms such as oral or inhaled formulations. Large-scale Phase 3 trials assessing long-term outcomes and integration strategies with existing interventions are imperative. Implementation science focusing on community acceptance, delivery models, and health system readiness will facilitate translation from trials to practice. Cumulatively, addressing these gaps will be crucial to realize the full potential of monoclonal antibody prophylaxis in malaria control and elimination.

CONCLUSION

Monoclonal antibody prophylaxis against Plasmodium falciparum represents an innovative, highly promising approach for malaria prevention in high-transmission settings. Advances in antibody engineering have yielded long-acting, potent monoclonal antibodies such as CIS43LS that achieve substantial protection against infection during endemic transmission seasons with single-dose administration. Clinical trials demonstrate favorable safety profiles and the feasibility of intravenous and subcutaneous delivery, establishing proof of concept for real-world use. Integration of monoclonal antibodies into existing malaria control platforms could provide critical protection for vulnerable populations where vaccines or chemoprevention are insufficient or non-adherent. However, barriers including costs, delivery logistics, and limited data in key demographic groups must be addressed. Future research and policy efforts are warranted to optimize dosing, expand clinical indications, and ensure equitable access. This evolving therapeutic class has the potential to significantly impact the global malaria burden and accelerate progress

towards elimination. Accelerate multisite large-scale clinical trials focusing on infants and pregnant women and invest in developing scalable, affordable delivery platforms for monoclonal antibody prophylaxis in malaria-endemic regions.

REFERENCES

1. Ogbonnia Egwu, C., Aloke, C., Chukwu, J., Agwu, A., Tsamesidis, I., E Offor, C., Ajuka Obasi, N., Aja, P.M.: A world free of malaria: It is time for Africa to actively champion and take leadership of elimination and eradication strategies. Afr Health Sci. 22, 627–640 (2022). https://doi.org/10.4314/ahs.v22i4.68
2. Erisa, K., Raphael, I., Ugwu O.P.C., Alum, E.U.: Exploration of Medicinal Plants Used in the Management of Malaria in Uganda. NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES. 1, 101–108 (2023)
3. Alum, E.U., Tufail, T., Agu, P.C., Akinloye, D.I., Obaroh, I.O.: Malaria pervasiveness in Sub-Saharan Africa: Overcoming the scuffle. Medicine. 103, e40241 (2024). https://doi.org/10.1097/MD.0000000000040241
4. Osei-Tutu, L., Kariuki, S.K., Lee, C.K., Fabre, R., Bii, D.K., Adjei, S., Oneko, M., Attobrah Sarfo, M.A., Ockenhouse, C.F., Schuerman, L., Buabeng, P.B.Y., Bakari, A., Atieno, C., Kotoh-Mortty, M.F., Otieno, K., Ntiamoah, Y., Sang, T., Bollaerts, A., Westercamp, N., Ansong, D., Agbenyega, T., Samuels, A.M., Ofori-Anyinam, O.: Sustained efficacy of the RTS,S/AS01E malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial. Lancet Glob Health. 13, e1723–e1736 (2025). https://doi.org/10.1016/S2214-109X(25)00272-4
5. Björkman, A., Benn, C.S., Aaby, P., Schapira, A.: RTS,S/AS01 malaria vaccine—proven safe and effective? Lancet Infect Dis. 23, e318–e322 (2023). https://doi.org/10.1016/S1473-3099(23)00126-3
6. Haine, V., Oneko, M., Debois, M., Ndeketa, L., Agyapong, P.D., Boahen, O., Harrison, S.B.E., Adeniji, E., Kaali, S., Kayan, K., Owusu-Agyei, S., French, N., Kariuki, S., Devadiga, R., Ogutu, B., Ansah, N.A., Orsini, M., Ansah, P.O., Maleta, K., Ong'echa, J.M., Phiri, V.K., Mzanga, P., Jere, T.M., Azongo, D.K., Mategula, D., Orimbo, J., Oduro, A.R., Otieno, W., Kaburise, M.B., Ababio, L.O., Sifuna, P.M., Amoit, S.K., Olewe, F., Oyieko, J.N., Achieng Oguk, E., Guerra Mendoza, Y., Awuni, D., Sing'oei, V., Onyango, I., Schuerman, L., Ochieng, B.O., Okoth, G.O., Nyangulu, W., Cherop, R.Y., Odera-Ojwang, P., Cravcenco, C., Chipatala, R., Roman, F., Savic, M., Asante, K.P.: Safety of RTS,S/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring study. Lancet Glob Health. 13, e995–e1005 (2025). https://doi.org/10.1016/S2214-109X(25)00096-8
7. Zoa, J.A., Njemguie Linjouom, R.M., Nyangono Ndongo, M., Nkeck, J.R.: Safety of RTS,S/AS01E vaccine for malaria in African children aged 5 to 17 months: A systematic review and meta-analysis of randomized controlled trials. PLOS Global Public Health. 5, e0004387 (2025). https://doi.org/10.1371/JOURNAL.PGPH.0004387
8. Malaria vaccines (RTS,S and R21), https://www.who.int/news-room/questions-and-answers/item/q-a-on-rts-s-malaria-vaccine
9. Hill, J., Bange, T., Hoyt, J., Kariuki, S., Jalloh, M.F., Webster, J., Okello, G.: Integration of the RTS,S/AS01 malaria vaccine into the Essential Programme on Immunisation in western Kenya: a qualitative longitudinal study from the health system perspective. Lancet Glob Health. 12, e672–e684 (2024). https://doi.org/10.1016/S2214-109X(24)00013-5
10. Osoro, C.B., Ochodo, E., Kwambai, T.K., Otieno, J.A., Were, L., Sagam, C.K., Owino, E.J., Kariuki, S., ter Kuile, F.O., Hill, J.: Policy uptake and implementation of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation. BMJ Glob Health. 9, e014719 (2024). https://doi.org/10.1136/BMJGH-2023-014719
11. Kelly, S.L., Malinga, J., Penny, M.A., Nawaz, S., Thompson, H., Gordon, S., Winskill, P., Hogan, A., Mulongeni, P., Verity, B., Ghani, A.: Comparing modelled impact and cost-effectiveness estimates for the RTS,S/AS01 malaria vaccine with evaluation results observed in phased pilot introductions PATH, Seattle, USA EXECUTIVE SUMMARY Overall assessment.
12. Surprising research results drive progress in malaria prevention | PATH, https://www.path.org/our-impact/articles/surprising-research-results-drive-progress/
13. Dimala, C.A., Kika, B.T., Kadia, B.M., Blencowe, H.: Current challenges and proposed solutions to the effective implementation of the RTS, S/ AS01 Malaria Vaccine Program in sub-Saharan Africa: A systematic review. PLoS One. 13, (2018). https://doi.org/10.1371/JOURNAL.PONE.0209744
14. Malaria Vaccines | Malaria | CDC, https://www.cdc.gov/malaria/php/public-health-strategy/malaria-vaccines.html
15. Aleshnick, M., Florez-Cuadros, M., Martinson, T., Wilder, B.K.: Monoclonal antibodies for malaria prevention. Molecular Therapy. 30, 1810 (2022). https://doi.org/10.1016/J.YMTHE.2022.04.001

16. World Health Organization: Monoclonal antibodies for malaria prevention: preferred product characteristics and clinical development considerations. (2023)
17. Ainebyoona, C., Egwu, C.O., Onohuean, H., Ugwu, O.P.C., Uti, D.E., Alum, B.N, Echegu, D.A. Mitigation of Malaria in Sub-Saharan Africa through Vaccination: A Budding Road Map for Global Malaria Eradication (2025). Ethiopian Journal of Health Sciences, 2025; 35(3): 205-217. doi: 10.4314/ejhs.v35i3.9. PMID: 40717722; PMCID: PMC12287706.
18. Lampejo, T.: Monoclonal antibodies for the prevention of Plasmodium falciparum malaria: a multi-target approach? Infect Dis. 56, 73–77 (2024). https://doi.org/10.1080/23744235.2023.2274897
19. Kayentao, K., Ongoiba, A., Preston, A.C., Healy, S.A., Doumbo, S., Doumtabe, D., Traore, A., Traore, H., Djiguiba, A., Li, S., Peterson, M.E., Telscher, S., Idris, A.H., Kisalu, N.K., Carlton, K., Serebryannyy, L., Narpala, S., McDermott, A.B., Gaudinski, M., Traore, S., Cisse, H., Keita, M., Skinner, J., Hu, Z., Zéguimé, A., Ouattara, A., Doucoure, M., Dolo, A., Djimdé, A., Traore, B., Seder, R.A., Crompton, P.D.: Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali. New England Journal of Medicine. 387, 1833–1842 (2022). https://doi.org/10.1056/NEJMOA2206966
20. Mezieobi, K.C., Alum, E.U., Ugwu, O.P.C., Uti, D.E., Alum, B.N., Egba, S.I., Ewah, C.M. Economic burden of malaria on developing countries: A mini review. Parasite Epidemiology and Control.30 (2025), e00435. https://doi.org/10.1016/j.parepi.2025.e00435
21. Ekpang II, J. E., Ekpang, P. O., Ainebyoona, C., Nwagu, K. E., Nwuruku, O. A., & Muhammad, K. (2025). Toward an ethical future for orphan drugs: balancing access, affordability, and innovation. *Journal of Medical Economics*, 1–24. https://doi.org/10.1080/13696998.2025.2577514

CITE AS: Mugisha Emmanuel K. (2026). Monoclonal Antibody Prophylaxis Against Plasmodium Falciparum Infection in High-Transmission Settings. RESEARCH INVENTION JOURNAL OF RESEARCH IN MEDICAL SCIENCES 5(1):87-91. https://doi.org/10.59298/RIJRMS/2026/518791